An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
Treating CLL with CALQUENCE® (acalabrutinib)
April 28th 2021, 12:30pm
Don’t let your disease define you
April 23rd 2021, 9:00pm
Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.
April 22nd 2021, 9:00pm
Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.
April 16th 2021, 12:00pm
Navigating life with blood cancer
March 17th 2021, 12:00pm
March 3rd 2021, 7:00pm
Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.
February 19th 2021, 9:30pm
February 19th 2021, 4:00pm
From the death of Bill Ludwig, the first patient to receive CAR-T cell therapy to treat his end-stage CLL, to a letter to the President urging him to grant patients with cancer and survivors priority access to the COVID-19 vaccine, here’s what’s happening in the cancer space this week.
February 19th 2021, 1:00pm
February 15th 2021, 4:00pm
The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.
How Can Cancer Survivors Help The Newly Diagnosed?
CURE Honors World Ovarian Cancer Day
Derazantinib May Demonstrate Promising Disease Control in Some Patients With Cholangiocarcinoma
You May Have Second Thoughts When Receiving a Cancer Diagnosis
